Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics

Chronic hepatitis C virus (HCV) infection is a major cause of liver disease worldwide. HCV infection is currently treated with IFNα plus ribavirin for 24 to 48 weeks. This demanding therapy fails in up to 50% of patients, so the use of pharmacogenetic biomarkers to predict the outcome of treatment w...

Descripción completa

Detalles Bibliográficos
Autores principales: Tavis, John E, Donlin, Maureen J, Aurora, Rajeev, Fan, Xiaofeng, Di Bisceglie, Adrian M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092093/
https://www.ncbi.nlm.nih.gov/pubmed/21345258
http://dx.doi.org/10.1186/gm222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092093/
https://www.ncbi.nlm.nih.gov/pubmed/21345258
http://dx.doi.org/10.1186/gm222

Ejemplares similares